0001323885-26-000007
SEC filingRevenue grew 14.9% on strong pain management and appendage sales; gross margin improved 29 bps, narrowing net loss.
AtriCure, Inc. describes itself as a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. The company focuses on providing products used by physicians during open-heart and minimally invasive surgical procedures. Afib affects over 59 million people worldwide, and the company believes increasing awareness and aging populations will drive diagnosis rates. AtriCure estimates that over 500,000 patients undergoing open-heart surgery annually are candidates for surgical ablation, yet less than 15% are currently treated, representing a significant growth opportunity.
The filing does not disclose formal reporting segments with revenue percentages. However, the business is described through three primary areas: cardiac ablation (for Afib treatment), left atrial appendage management (LAAM), and pain management. The cardiac ablation segment includes products for open and minimally invasive ablation using radio frequency or cryogenic energy. LAAM products center on the AtriClip system. Pain management solutions include cryoablation probes for Cryo Nerve Block therapy.
Key products include: Isolator Synergy clamps (FDA-approved for persistent and long-standing persistent Afib in concomitant open-heart surgery), EnCompass clamp (cleared for cardiac soft tissue ablation), EnCapture clamp (enhanced geometry), cryoICE cryoablation system (used for ablation and cryoanalgesia), EPi-Sense Systems (FDA-approved for minimally invasive Hybrid AF Therapy), cryoSPHERE probes (for Cryo Nerve Block, used in over 100,000 procedures), cryoXT probes (new for amputation pain management), and AtriClip system (most widely sold LAA management device with over 750,000 patients treated). Additional products include LARIAT System, Lumitip dissector, Glidepath guides, and Subtle Cannula.
AtriCure sells products through a direct sales force in the United States, Germany, France, the United Kingdom, the Benelux region, Australia, and Canada. In other international markets, sales are made through distributors. The business is primarily transacted in U.S. dollars; direct sales outside the U.S. use Euros, British Pounds, Australian Dollars, or Canadian Dollars. No key customer concentration is disclosed.
The primary competitor in the cardiac surgery market is Medtronic, plc, offering surgical ablation products and LAAM devices. For standalone Afib treatment, endocardial catheter devices are used by electrophysiologists, but they are not FDA-indicated for long-standing persistent Afib. In the post-operative pain market, no U.S. companies currently pursue cryo nerve block therapies, though some international competitors exist. AtriCure's Hybrid AF Therapy and Isolator Synergy are the only FDA-approved devices for long-standing persistent Afib.
The company's strategy is organized around five pillars: (1) New Product and Procedure Innovation—developing products for new or existing markets; (2) Investments in Clinical Science—conducting landmark trials like LeAAPS and BoxX-NoAF to validate outcomes and expand indications; (3) Build Physician and Societal Relationships—engaging with key opinion leaders and societies to increase awareness; (4) Provide Training and Education—offering in-person and virtual training programs, including simulation models; (5) Evaluate Acquisition Opportunities—being opportunistic about acquisitions that meet strategic and financial criteria.
As of December 31, 2025, AtriCure had approximately 1,350 employees. The U.S. sales team consists of about 330 employees, and the international sales team includes approximately 75 employees focused on direct markets. The company reports low voluntary turnover (consistently at or below 10%) and has been recognized as a Top Workplace and Great Place to Work. AtriCure emphasizes talent attraction and development through programs like AMPLIFY leadership development, Manager Foundations Certification, and AtriCure YOUniversity.
Revenue for 2025 reached $534.5M, a 14.9% increase from $465.3M in 2024. Growth was driven by strong performance in pain management (+32.5%), open ablation (+16.3%), and appendage management (+17.5%), partially offset by a 31.2% decline in minimally invasive ablation as physicians shifted to PFA catheters. Gross profit rose 15.3% to $400.8M, with gross margin expanding 29 bps to 75.0% due to favorable product mix, despite higher product costs and less favorable geographic mix. Operating loss improved significantly from -$40.0M to -$9.4M, driven by revenue growth and operating leverage. R&D expenses increased 3.2% to $99.2M, primarily due to higher personnel costs and clinical trial expenses for LeAAPS and BoxX-NoAF, partially offset by a $6.0M decrease in PFA co-development payments. SG&A expenses rose 6.7% to $311.0M, reflecting headcount growth and higher share-based compensation. Other expense declined to $0.7M from $3.7M, helped by the absence of a $1.4M loss on debt extinguishment from Q1 2024. Net loss narrowed to -$11.4M from -$44.7M, a 74.4% improvement.
Revenue by product line showed divergent trends. Open ablation grew 16.3% to $143.8M, supported by the EnCompass clamp. Pain management surged 32.5% to $81.9M, aided by the cryoSPHERE MAX probe launch. Appendage management increased 17.5% to $178.1M, driven by the AtriClip FLEX-Mini device. In contrast, minimally invasive ablation fell 31.2% to $31.5M due to reduced hybrid procedures as physicians adopted PFA catheters. Geographically, US revenue rose 13.7% to $435.4M, while international revenue grew 20.2% to $99.2M (17.5% constant currency), with gains across all franchises and regions. Cost of revenue increased $16.0M to $133.7M, driven by higher volumes, while gross margin benefited from product mix shifts toward higher-margin open ablation and pain management products.
Management highlighted several strategic initiatives for future growth. The LeAAPS trial completed enrollment of 6,573 patients in July 2025, with follow-up ongoing, supporting potential prophylactic LAA exclusion indications. The BoxX-NoAF trial began enrollment in October 2025 to evaluate concomitant ablation and LAA exclusion for reducing postoperative AF. New product development includes the cryoICE cryoXT probe for amputation pain (launched Q3 2025) and the AtriClip PRO-Mini for minimally invasive LAA management (launched H2 2025). A novel dual energy platform integrating PFA and advanced RFA was used in first-in-human treatments in Q4 2025, with a clinical trial expected in the coming year. The company expects continued investment in R&D, clinical science, and physician education to drive adoption. Liquidity remains solid with $167.4M cash and $62.8M available under the amended ABL facility. Management anticipates sufficient capital for at least 12 months, though acknowledges risks from inflation and potential dilution if additional financing is needed.
As of December 31, 2025, AtriCure held $167.4 million in cash and cash equivalents, up from $122.7 million a year earlier. Total debt stood at $61.9 million under an asset-based revolving credit facility (ABL), with an additional financing obligation of $6.2 million from a failed sale-and-leaseback transaction. Shareholders' equity was $491.9 million, reflecting accumulated deficit of ($413.2 million) offset by paid-in capital. Inventory was $78.5 million, and accounts receivable net of allowance was $66.7 million. No investments were held. The ABL facility was amended in January 2026, extending maturity to January 2029 and reducing interest margins.
The Notes disclose notable purchase commitments: (1) a clinical trial management agreement for the LeAAPS trial requiring payments of $13.4 million in 2025, with variable future payments upon milestones; (2) a non-cancellable cloud computing arrangement of $3.6 million with payments starting March 2026. Additionally, the failed sale-and-leaseback transaction generates future rental payments of approximately $38.5 million over a 15-year term for the expansion, though these are not purchase commitments per se. Contingent consideration for the PFA license has a maximum payout of $28 million, but milestone payments are expensed as achieved ($6 million in 2025). The SentreHEART contingent consideration was deemed remote.
AtriCure has no share buyback program or dividend policy. Capital expenditures were $9.1 million in 2025, down from $11.5 million in 2024. Debt activity includes issuance of $61.9 million in the ABL facility in 2024, with a subsequent $0.9 million paydown in January 2026 via the First Amendment. No other debt issuance or repayment occurred in 2025. The company does not disclose any other capital allocation programs.
The company operates as a single reporting segment. However, Note 11 provides revenue breakdown by product type and geography. In 2025, total revenue was $534.5 million: Open Ablation $184.9M (35%), Minimally Invasive Ablation $39.8M (7%), Pain Management $89.6M (17%), and Appendage Management $220.2M (41%). US revenue was $435.4M (81%), International $99.2M (19%). No operating income or margin is reported at product level.
AtriCure faces significant legal risks, particularly around FDA regulations. Without additional approval, the company cannot promote products for Afib, stroke prevention, or post-operative Afib, which are key growth drivers. Off-label promotion could lead to fines and injunctions. The company also relies on FDA clearance for product modifications; failure to obtain clearance could result in recalls. Compliance with QMSR and other manufacturing regulations is critical, and any adverse inspection may disrupt production.
The company depends on single or limited-source third-party suppliers for components, sterilization, and logistics. Any interruption could impair ability to meet demand. Manufacturing is highly centralized in Ohio, with no backup facility, exposing the company to natural disasters or other disruptions. Cybersecurity breaches and loss of key personnel are also ongoing operational risks.
AtriCure has a history of net losses and accumulated deficit. Quarterly results fluctuate due to uncertain product adoption. Inventory management is challenging, and goodwill impairment could materially reduce asset value. The company is subject to credit risk from international customers and must comply with credit agreement covenants.
Competition from catheter ablation, drugs, and other devices may reduce market share. Macroeconomic downturns could lower procedure volumes and hospital staffing, while changes in reimbursement policies could limit product use. Negative clinical data or publicity could further hinder adoption.
Growth requires effective management of expansion, including hiring and training. Stock price volatility, lack of dividends, and anti-takeover provisions are common stock risks. Trade policies and currency fluctuations may affect international sales.
The provided document excerpt does not contain any figures from the cash flow statement. The text includes the auditor's report and the balance sheet header, but the cash flow statement itself is not included. Therefore, no analysis can be performed.